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38 Poster Session Icount (\150K/ul) was the only significant predictor when the anal-
ysis was restricted to NHL patients mobilized with chemotherapy
(odds ratio 8.9, p\ 0.001). Conclusions: A significant proportion
(18%) of patients with NHL fails to mobilize stem cells. Use of fil-
grastrim without chemotherapy was associated with high failure
rate, but this needs to be confirmed in a larger comparative study.
For patients who were mobilized with chemotherapy, low platelet
count is the most significant predictive factor.
Univariate Analysis in Patients with NHL
N N Failed % Fail OR1 95% CI2 pPlatelet Count
\150 K 34 14 41
$150 K 107 12 11 0.2 0.1–0.4 \0.001Cellularity
\30% 44 13 30 2.7 1.1–6.5 0.02
$30% 97 13 13Regimen
Ifos/VP16 96 12 13
G-CSF alone 13 8 62 11.2 3.1–40 \0.001
Cyclophosphamide 14 3 21 1.9 0.5–7.8 0.4Other 18 3 17 1.4 0.3–5.6 0.61Odds Ratio.
2Confidence Interval.97
POSITRON EMISSION TOMOGRAPHY IDENTIFIES A DIFFERENTIAL
PATTERN OF BONE MARROW FDG UPTAKE IN ‘‘POOR’’ AND ‘‘GOOD’’
PERIPHERAL STEM CELL MOBILIZERS
Marcacci, G.1, Caraco`, C.2, D’Arena, G.1, Aloj, L.2, Corazzelli, G.1,
Frigeri, F.1, Lastoria, S.2, Pinto, A.1 1National Cancer Institute ‘‘Fon-
daz. Pascale’’, Naples, Italy; 2National Cancer Institute ‘‘Fondaz. Pas-
cale’’, Naples, Italy.
The use of prophylactic G-CSF is associated to the increase of
bone marrow (BM) fluorodeoxyglucose (FdG) uptake as detected
by Positron Emission Tomography (PET). In contrast, no data is
available as to changes in BM FdG-uptake during peripheral blood
stem cell (PBSC) mobilization. This study was aimed at investigat-
ing patterns of BMFdGuptake duringmobilization as quantified by
Standardized Uptake Value (SUV) determinations. We also evalu-
ated whether PET scanning may turn of value for identifying good
and poor mobilizers. To our knowledge this is the first PET-based
study in this setting. Methods Seventeen patients(pts)(M/F 5 10/
7), median age 51 yrs (r 28–65), with relapsed lymphoma (NHL/
HD5 13/4) without BM involvement, were accrued after informed
consent. Baseline PET was obtained at relapse, before salvage ther-
apy and anyCSF administration. After salvage regimes pts weremo-
bilized by VRL/CTX or ARA-C; G-CSF (10 mg/kg/d) was given
from day 16 through apheresis. PET scans were obtained on day
19 or 110 (after nadir with a WBC . 1000/ml). SUVmax and av-
erage (avg) were measured (whole lumbar spine and bilateral iliac
regions) and compared to SUV of the same BM regions at baseline
PET. The aim was to calculate a BM specific D-SUV (mobilizing vs
steady-state D-SUV) for each single patient. ResultsTwelve pts mo-
bilized PBSC (median CD34 peak 39.99/ml, r 23.28–280.58/ml; me-
dian CD34 in the harvest 3.3 106/Kg, r 2.1–12.5) while 5 pts were
poor mobilizers (median CD34 peak 10.9/ml, r 7.5–14.1/ml). In the
group of good mobilizers, apheresis was performed at CD34 peak
(day 111,114), with a median of 1 apheresis/pt (r 1–2). Unexpect-
edly, effective mobilization was associated with a low BM uptake of
FdG: median BM D-SUVmax and D-SUVavg of 2.0 (r 1.0–3.8) and
2.3 (r 0.9–3.9), respectively. In contrast, poor mobilizers displayed
a median D-SUVmax and D-SUVavg of 4.7 (r 2.4–12.8) and 5.9
(r 4.1–14.2), respectively.
Conclusions: While FdG-BM uptake usually increases upon
CSF administration, our results suggest that PBSC mobilization
may be associated with a more complex metabolic pattern of BM
as detected by PET. We documented that, 48 to 72 hrs beforeCD34 peak, poor mobilizers display a higher FdG-BM uptake
(D-SUV . 3) as compared to good mobilizers (D-SUV\ 3). These
preliminary results indicate that BM PETmay represent a new tool
for early identification of poor mobilizers allowing a timely modifi-
cation of the mobilization strategy to possibly rescue the procedure.98
RADIO-IMMUNOTHERAPY FOR LOW GRADE NON-HODGKIN’S LYM-
PHOMAMAY IMPAIR THE ABILITY TOMOBILIZE AUTOLOGOUS PERIPH-
ERAL BLOOD STEM CELLS
Raptis, A., Mapara,M., Bilodeau, A., Hornyak,M., Agha,M.E. UPMC
Cancer Centers/University of PittsburghMedical Center, Pittsburgh, PA.
High dose chemotherapy and autologous stem cell transplanta-
tion (ASCT) is a proven effective treatment modality for patients
with relapsed non-Hodgkin’s lymphoma. Radioimmunotherapy
(RIT) with 90Y-ibritumomab tiuxetan has been shown to be useful
in patients with relapsedNHL, but is now being used in the upfront
setting for patients with low gradeNHL, as some protocols now of-
fer abbreviated chemotherapy courses followed by RIT. As patients
relapse high dose therapy and ASCT become a valuable option but
the effect of RIT on the stem cell collection becomes an important
issue. We report four patients with follicular NHL who relapsed
within 6–8 months after RIT were treated with salvage chemother-
apy then mobilized with Cyclophosphamide and G-CSF. Two pa-
tients were heavily pre-treated for multiple relapses, but two had
only one relapse following upfront RIT. Only 2/4 patients mobi-
lized successfully, but with low yield. One of the patients developed
secondary leukemia, 6 months after ASCT. Surprisingly, the mobi-
lization failure patients were young, not heavily treated (had 6–7 cy-
cles of chemotherapy including the upfront and salvage therapy), no
exposure to external beam radiotherapy, but had heavy tumor bur-
den at initial presentation. Our results suggest that mobilization
failure following RIT is much higher that would have been pre-
dicted. Caution should be exercised when offering RIT to patients
with bulky disease low grade lymphoma as part of the upfront ther-
apy, as rapid relapsesmay not be salvageable with high dose therapy,
given the high rate of mobilization failure even in patients who are
not heavily treated. The long term safety of RIT andmyelodysplasia
in such patients is also an important concern, given the short inter-
val of tAML in our patient.99
PREDICTORS OF OUTCOME OF MANTLE CELL LYMPHOMA IN PATIENTS
WITH PROGRESSIVE DISEASE FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT)
Al-Farsi, K., Nagy, T., Keating, A., Crump, M., Kuruvilla, J. Princess
Margaret Hospital, Toronto, ON, Canada.
Introduction: Mantle Cell Lymphoma (MCL) is a subgroup of
malignant lymphomas that is considered incurable with conven-
tional therapy.While ASCT has improved progression free survival
(PFS), relapse remains a major issue. For patients (pts) who relapse
after ASCT, there is little information on the predictors of outcome
and optimal treatment strategy. We reviewed pts with progressive
disease following ASCT in an attempt to identify predictors of sub-
sequent outcome.Method:We retrospectively reviewed our com-
puterized database and charts of pts undergoing ASCT from May
1987 - Jul 2006. Of 47 pts, 21 relapsed after ASCT; 20 had adequate
data on subsequent therapy and were analyzed for factors influenc-
ing progression free survival (PFS) and overall survival (OS) using
Kaplan-Meier and Cox-Proportional Hazards analyses. Results:
Pt characteristics: At relapse post-ASCT, median age was: 56 years
(range 40–69). Stage 3 or 4: 16. High LDH: 8. Disease status of
ASCT: CR1/PR1 5 9, .CR1/PR1 5 11. IPI scores: low (n 5 9),
low-intermediate (n 5 8), high-intermediate (n 5 2) and high
(n 5 1). FLIPI scores: low (n 5 10), intermediate (n 5 4) and
high (n 5 6). Seven had bone marrow involvement, 3 had involve-
ment of peripheral blood and 5 had splenomegaly. Eighteen pts re-
ceived subsequent treatment: R-FCM: 4, Rituximab: 1, Radiation
Poster Session I 39alone: 3, other combination chemotherapy: 9 and 1 underwent re-
duced intensity allogeneic transplantation. Two pts were not fit to
receive further treatment and had rapidly progressive disease
(PD). Of the treated pts, 6 achieved CR (4 subsequently pro-
gressed), 5 PR and 7 had PD. Eleven pts remain alive (only 2 in
CR) with PD accounting for all deaths. With a median follow-up
of 31 months (m) post relapse for living pts, median PFS from the
time of relapse post-ASCT was 5 m and OS was 34 m. No signifi-
cant predictors of PFS could be identified. For OS, univariate anal-
ysis identified time to relapse (TTR; p5 0.011), performance status
(PS; p5 0.010) and total IPI score (p5 0.041) as being statistically
significant. Only TTR remained significant on the multivariate
model. TTR less than 12 months portends a very poor outcome
(2 year OS 0% compared to 62% form TTR .12 m; p\ 0.001).
Conclusion: Pts with MCL who relapse after ASCT do poorly, es-
pecially those relapsing within one year of ASCT. New therapeutic
approaches incorporating maintenance therapy post-ASCT or the
use of novel agents such as bortezomib or mTOR inhibitors should
be explored in this group.100
FLUID RELATED COMPLICATIONS WITH FILGRASTIM (G-CSF) 10 MCG/
KG ONCE DAILY VERSUS 5 MCG/KG TWICE DAILY IN AMYLOIDOSIS PA-
TIENTS UNDERGOING PERIPHERAL BLOOD STEM CELL MOBILIZATION
Perreault, S.K.1, Burzynski, J.A.1, Hoskin, T.L.2, Leung, N.3,
Buadi, F.K.3, Dispenzieri, A.3, Hayman, S.R.3, Kumar, S.K.3,
Lacy, M.Q.3, Gertz, M.A.3, Wolf, R.C.1 1Mayo Clinic, Rochester,
MN; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Rochester, MN.
Background:High dosemelphalan followed by peripheral blood
stem cell (PBSC) transplantation is an established therapy for AL
amyloidosis. One limitation is the frequent fluid related complica-
tions that occur during PBSC mobilization (Blood 2004:1143a).
The development of fluid related complications during mobiliza-
tion predicts decreased survival after PBSC transplant (Blood
2005;106:3353). At Mayo Clinic, G-CSF 10 mcg/kg once daily
was the standard until 2004. In attempt to reduce fluid related com-
plications the practice changed to G-CSF 5 mcg/kg twice daily in
July 2004. It is unknown if this change impacted the incidence of
fluid related complications during PBSC mobilization. Methods:
We conducted a retrospective evaluation of patients with amyloid-
osis undergoing PBSCmobilization at Mayo Clinic. Following IRB
approval, patients were identified by reviewing theMayoClinic dys-
proteinemia data base and data extracted from the medical record.
Forty-six patients from the once daily and 22 patients from the twice
daily were excluded due to use of mobilization agents in addition to
G-CSF, second mobilization, syngeneic transplant or consent re-
fusal. A fluid related complication was defined as new peripheralComparison of Complications based on G-CSF Schedule of
Administration
Once
daily
Filgrastim
n 5 123 N (%)
Twice
daily
Filgrastim
n 5 182 N (%) p value
Fluid Complications 63 (50) 93 (51) 0.9
Hospitalization 28 (23) 24 (13) 0.03
Hospitalization related
to fluid complication
21 (17) 10 (5) 0.001
Diuretic adjustment
needed
42 (34) 89 (49) 0.012
Non-pharmacological
intervention*
10 (8) 9 (5)
Death prior to PBSC
Transplant
2 (1.6) 4 (2.2)
Patient did not undergo
PBSC transplant
9 (7.3) 37 (20)
*Thoracentesis, Paracentesis, Hemodialysis, Pleurodesis, and Me-
chanical Ventilation.edema, pleural effusion or ascites, or initiation of supportive therapy
(diuretics, albumin, or dopamine) to promote diuresis. Results:
From 7/98 to 8/03, 123 patients received once daily G-CSF.
From 7/04 to 8/07, 182 patients received twice daily G-CSF. Organ
involvement was similar in both series; single organ (43% vs 36%; p
5 0.2), two organs (38% vs 62%; p 5 0.5) and 3 or more organs
(22% vs 26%; p5 0.5).Most patients had either kidney involvement
(65% vs 71%; p5 0.2) or heart involvement (51% vs 57%; p5 0.3).
Baseline edema (61% vs 53% (p 5 0.06)) and baseline diuretic use
(58% vs 55% (p 5 0.7)) was similar in both groups. Fluid related
complications occurred with similar frequency regardless of admin-
istration schedule, 50% vs 51% (p5 0.9). Two patients in the once
daily and 4 patients in the twice daily administration died prior to
PBSC transplant. In patients that received a PBSC transplant, sur-
vival was similar at day 100; 88% vs 92% and one year; 83% vs 88%
(p 5 0.6). Conclusion: Changing from once daily to twice daily
G-CSF administration in patients with amyloidosis did not impact
the incidence of fluid related complications or mortality at day 100
or one year after PBSC transplant.101
PHASE II TRIAL EVALUATING APREPITANT (AP) FOR PREVENTION OF
NAUSEA AND VOMITING SECONDARY TO HIGH-DOSE CYCLOPHOSPHA-
MIDE (CY) ADMINISTERED TO PATIENTS UNDERGOING AUTOLOGOUS
(A) PERIPHERAL BLOOD PROGENITOR CELL (PBPC) MOBILIZATION
Abidi, M.H.1,2, Abrams, J.1,2, Ibrahim, R.3, Ayash, L.1,2, Cronin, S.3,
Al-Khadimi, Z.1,2, Lum, L.1,2, Ratanatharathorne, V.1,2, Uberti, J.1,2
1Wayne State University, Detroit, MI; 2Barbara Ann Karmanos Cancer
Center, Detroit,MI; 3Eugene AppelbaumCollege of Pharmacy and Allied
Health Professions, Detroit, MI.
Background:Adequate PBPCmobilization in the range of 2–5
106 CD341 cells/kg body weight is a prerequisite for administration
of high-dose chemotherapy and A-PBPC transplant. Cy and filgras-
tim combination provides a better PBPC yield as compared to fil-
grastim, which has a failure rate of 15–20%. In this setting, high-
dose Cy is associated with significant nausea and vomiting. Ap is
a new antiemetic that is a Neurokinin-1 receptor antagonist and
may reduce the incidence of this side effect. We have conducted
a phase II trial evaluating efficacy and safety of adding Ap to stan-
dard antiemetic combination of 5-HT3 antagonists and adjusted
dose of corticosteroids. Primary objective of this study was the con-
trol of acute vomiting without the use of rescue medications at 24
hours post Cy. The data of the first interim report are presented.
Methods: From May 2005 to May 2007, 22 pts were enrolled,
four of whom are not evaluable for response. Three pts did not re-
ceive Ap; one withdrew consent after a single dose. All received Cy 4
gm/m2 and filgrastim (10–16 mcg/kg/d) for stem cell mobilization.
Granisetron 1 mg, dexamethasone 10 mg and Ap 125 mg was ad-
ministered orally 1 hour before Cy followed by Ap 80 mg once daily
 2 days. This study used Simon’s optimal two-stage design con-
strained to fewer than 40 pts with 10% type I error and 85% statis-
tical power. Ap is considered effective if it prevents nausea and
vomiting in at least 65% of patients. Ap is judged ineffective if the
rate of vomiting control was 45% or less. Results: Ten (55%) of
18 response-evaluable pts had no vomiting episodes and received
no rescue medications during the first 24 hours following Cy. Of
those who did not achieve the primary endpoint, four pts reported
no vomiting episodes but received rescue medications. The other
four pts had at least one vomiting episode and one received rescue
anti-emetic. Ten pts had no delayed vomiting (25–120 hrs). Ten
pts reported no nausea in 24 hours and five pts experienced mild
nausea. Only 6/18 (33%) pts experienced moderate to severe de-
layed nausea (25–120 hrs). No toxicities related to Ap were noted
for any patients. All pts had adequatemobilization of stem cells (me-
dian CD341: 7.57  106/kg) and proceeded to A-PBPC transplant.
Conclusion: The results of this interim analysis justify continua-
tion to stage 2 with enrollment of 17more patients. Ap has potential
to effectively control nausea and emesis in pts receiving high-dose
Cy.
